Biotech gets $50m up front, up to $650m in milestones, significant royalties and the option to co-promote emricasan in NASH in the US. Novartis also may combine the caspase inhibitor with its Phase II FXR agonist.
The broad-based competition in non-alcoholic steatohepatitis (NASH) took another turn Dec. 19, as Conatus Pharmaceuticals Inc. signed an option, collaboration and commercialization agreement with Novartis AG around its caspase inhibitor emricasan, currently in Phase IIb for both NASH cirrhosis and NASH fibrosis.
The deal brings Conatus $50m up front, a convertible loan of up to $15m from Novartis, a $7m exercise fee...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Francesco Hofmann, head of R&D at the mid-sized French group, tells Scrip that its strategy of not playing in the spaces that are dominated by big pharma is paying off.
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
